摘要
This article presents a case of a patient with relapsed esthesioneuroblastoma (ENB), an aggressive rare tumor that arises from the specialized sensory epithelial olfactory cells in the skull base area, which was initially treated with endoscopic surgery, followed by adjuvant radiotherapy. After local relapse, new surgical approaches and subsequent lines of platin-based chemotherapy were performed. A PET-CT with <sup>68</sup>GALIUM DOTATATOC (PET-DOTATOC) showed intense uptake of disease, compatible with the presence of somatostatin receptors, in the face, nodes, liver, bones, and meningeal area. Treatment with 4 cycles of <sup>177</sup>Lutetium-Dotatate was performed, followed by maintenance octreotide, with a major radiological and clinical response that is lasting more than 1 year after treatment. This article describes a rare case of a skull-base tumor, with multiple recurrences, in which disease control was achieved with a targeted Peptide Receptor Radionuclide Therapy (PRRT) with <sup>177</sup>Lutetium-Dotatate, and discusses factors that could influence the incorporation of this form of therapy. Previous case reports proved the potential efficacy of this therapy usually given for low-grade neuroendocrine tumors and will be carefully reviewed.
This article presents a case of a patient with relapsed esthesioneuroblastoma (ENB), an aggressive rare tumor that arises from the specialized sensory epithelial olfactory cells in the skull base area, which was initially treated with endoscopic surgery, followed by adjuvant radiotherapy. After local relapse, new surgical approaches and subsequent lines of platin-based chemotherapy were performed. A PET-CT with <sup>68</sup>GALIUM DOTATATOC (PET-DOTATOC) showed intense uptake of disease, compatible with the presence of somatostatin receptors, in the face, nodes, liver, bones, and meningeal area. Treatment with 4 cycles of <sup>177</sup>Lutetium-Dotatate was performed, followed by maintenance octreotide, with a major radiological and clinical response that is lasting more than 1 year after treatment. This article describes a rare case of a skull-base tumor, with multiple recurrences, in which disease control was achieved with a targeted Peptide Receptor Radionuclide Therapy (PRRT) with <sup>177</sup>Lutetium-Dotatate, and discusses factors that could influence the incorporation of this form of therapy. Previous case reports proved the potential efficacy of this therapy usually given for low-grade neuroendocrine tumors and will be carefully reviewed.
作者
Gabriela Dombrowski
Laura Fernandes Ferreira Dalcin
Francisco Assis Coelho
Patricia Massucheto Ledesma
Daniel Herchenhorn
Gabriela Dombrowski;Laura Fernandes Ferreira Dalcin;Francisco Assis Coelho;Patricia Massucheto Ledesma;Daniel Herchenhorn(Department of Clinical Oncology, Instituto D’Or de Pesquisa e Ensino, Rio de Janeiro, Brazil;Clínica de Diagnóstico por Imagem CDPI, DASA, Instituto D’Or de Pesquisa e Ensino, Rio de Janeiro, Brazil;Clínica de Medicina Nuclear Villela Pedras, Clínica de Diagnóstico por Imagem CDPI, DASA, Rio de Janeiro, Brazil)
